跳至主要内容
临床试验/NCT01974323
NCT01974323已完成3 期

A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris

Almirall, S.A.0 个研究点目标入组 2,238 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
2,238
主要终点
Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)

研究概览

简要总结

This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.

详细描述

This is a multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to assess the safety and efficacy of dapsone 7.5% gel versus vehicle administered topically once daily for 12 weeks in patients with acne vulgaris.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of acne vulgaris
  • Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight, tanning beds) throughout the study

排除标准

  • Severe cystic acne, acne conglobata, acne fulminans, or secondary acne
  • Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling, comedo extraction) in the past week
  • Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]), retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks
  • Use of birth control pills strictly for acne control

研究组 & 干预措施

Dapsone Gel

Experimental

Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

干预措施: Dapsone Gel (Drug)

Dapsone Gel Vehicle

Placebo Comparator

Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

干预措施: Dapsone Gel Vehicle (Drug)

结局指标

主要结局

Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)

时间窗: Week 12

The Investigator evaluated the patient's acne severity using the 5-point GAAS scale with 0 being none and 4 being severe. The complete scale is as follow: Grade 0 (none) = No evidence of facila acne vulgaris; Grade 1 (minimal) = Few noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) may be present, no nodulo-cyctic lesions are allowed; Grade 2 (mild) = Several to many noninflammatory lesions (comedones) are present, a few inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 3 (moderate) = Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present, no nodulo-cystic lesions are allowed; Grade 4 (severe) = Significant degree of inflammatory disease, papules/pustules are a predominant feature, a few nodulo-cystic lesions may be present, comedones may be present.

Change From Baseline in Inflammatory Facial Lesion Counts

时间窗: Baseline, Week 12

The Investigator evaluated the patient's inflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).

Change From Baseline in Noninflammatory Facial Lesion Counts

时间窗: Baseline, Week 12

The Investigator evaluated the patient's noninflammatory lesions (papule, pustule and nodule/cyst). A negative change from baseline indicates a reduction in lesion counts (improvement) and a positive change from baseline indicates an increase in lesion counts (worsening).

次要结局

  • Change From Baseline in the 9-Item ASIS Sign Domain Score(Baseline, Week 12)
  • Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Redness on a the 5-Point ASIS Scale(Baseline, Week 12)
  • Change From Baseline in Total Lesion Counts(Baseline, Week 12)
  • Percentage Change From Baseline in Total Lesion Counts(Baseline, Week 12)
  • Percentage of Patients Reporting "Very Good" or "Excellent" on Item 10 of the 5-Point Acne Symptom Impact Scale (ASIS)(Week 12)
  • Percentage of Patients Reporting at Least a 1-Grade Improvement From Baseline in Facial Oiliness on a the 5-Point ASIS Scale(Baseline, Week 12)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验